572 related articles for article (PubMed ID: 12444548)
1. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.
Billottet C; Janji B; Thiery JP; Jouanneau J
Oncogene; 2002 Nov; 21(53):8128-39. PubMed ID: 12444548
[TBL] [Abstract][Full Text] [Related]
2. FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo.
Jouanneau J; Plouet J; Moens G; Thiery JP
Oncogene; 1997 Feb; 14(6):671-6. PubMed ID: 9038374
[TBL] [Abstract][Full Text] [Related]
3. Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells.
Malavaud B; Pedron S; Sordello S; Mazerolles C; Billottet C; Thiery JP; Jouanneau J; Plouët J
Oncogene; 2004 Sep; 23(40):6769-78. PubMed ID: 15273729
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
[TBL] [Abstract][Full Text] [Related]
5. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
Hajitou A; Sounni NE; Devy L; Grignet-Debrus C; Lewalle JM; Li H; Deroanne CF; Lu H; Colige A; Nusgens BV; Frankenne F; Maron A; Yeh P; Perricaudet M; Chang Y; Soria C; Calberg-Bacq CM; Foidart JM; Noël A
Cancer Res; 2001 Apr; 61(8):3450-7. PubMed ID: 11309307
[TBL] [Abstract][Full Text] [Related]
8. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression.
Deroanne CF; Hajitou A; Calberg-Bacq CM; Nusgens BV; Lapière CM
Cancer Res; 1997 Dec; 57(24):5590-7. PubMed ID: 9407972
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line.
Udayakumar TS; Nagle RB; Bowden GT
Prostate; 2004 Jan; 58(1):66-75. PubMed ID: 14673954
[TBL] [Abstract][Full Text] [Related]
11. Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells.
Okada-Ban M; Moens G; Thiery JP; Jouanneau J
Oncogene; 1999 Nov; 18(48):6719-24. PubMed ID: 10597279
[TBL] [Abstract][Full Text] [Related]
12. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
Zhang L; Kharbanda S; Hanfelt J; Kern FG
Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
[TBL] [Abstract][Full Text] [Related]
13. [Impact on tumor angiogenesis and tumor progression of expression of the 18 kd and 24 kd isoforms of FGF-2].
Okada-Ban M; Grassi M; Plouet J; Thiery JP; Jouanneau J
Pathol Biol (Paris); 1999 Apr; 47(4):375-9. PubMed ID: 10372408
[TBL] [Abstract][Full Text] [Related]
14. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
15. The community effect in FGF-1 mediated tumor progression of a rat bladder carcinoma does not involve a direct paracrine signaling.
Jouanneau J; Moens G; Thiery JP
Oncogene; 1999 Jan; 18(2):327-33. PubMed ID: 9927189
[TBL] [Abstract][Full Text] [Related]
16. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
Giri D; Ropiquet F; Ittmann M
Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
[TBL] [Abstract][Full Text] [Related]
17. Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor.
Wellstein A; Lupu R; Zugmaier G; Flamm SL; Cheville AL; Delli Bovi P; Basilico C; Lippman ME; Kern FG
Cell Growth Differ; 1990 Feb; 1(2):63-71. PubMed ID: 1964794
[TBL] [Abstract][Full Text] [Related]
18. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.
Etoh T; Inoue H; Tanaka S; Barnard GF; Kitano S; Mori M
Cancer Res; 2001 Mar; 61(5):2145-53. PubMed ID: 11280779
[TBL] [Abstract][Full Text] [Related]
19. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
Ogawa T; Takayama K; Takakura N; Kitano S; Ueno H
Cancer Gene Ther; 2002 Aug; 9(8):633-40. PubMed ID: 12136423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
